Transaction details
Director Jeffrey Stein of IDEAYA Biosciences, Inc. (NASDAQ: IDYA) executed a purchase of 50,000 common shares on March 2, 2026, representing a total outlay of $1.65 million. The filing shows the shares were acquired at a weighted average price of $32.9578, with individual trade prices spanning from $32.743 to $33.1999. After the purchase, Stein is recorded as directly owning 54,281 shares of IDEAYA. The filing also notes that he indirectly owns 3,363 shares held by his son.
Share performance and valuation context
The insider acquisition took place while IDEAYA shares traded at $33.04, a price that reflects a 73% gain over the prior 12 months. According to InvestingPro analysis cited in the filing, the stock is trading near its Fair Value estimate of $33.17. The company is also described as maintaining a solid near-term financial position, with liquid assets exceeding its short-term obligations. The InvestingPro service is reported to offer 11 additional exclusive tips for IDYA subscribers.
Clinical and corporate developments
Separately, IDEAYA announced the enrollment of the first patient in a Phase 1 study of IDE034, a bispecific antibody-drug conjugate being evaluated as a cancer therapy. The trial is designed to assess the safety, tolerability, and pharmacokinetics of IDE034 as a monotherapy, with plans to investigate combination regimens with other agents at a later stage.
The company also named Dr. Theodora Ross as Chief Development Officer. In this role, she will lead early clinical development efforts and play a role in shaping the firm’s research strategy.
Analyst perspectives
Several research firms continued to express favorable views on IDEAYA. Cantor Fitzgerald reiterated an Overweight rating, citing expectations for forthcoming trial results. Citizens maintained a Market Outperform rating, highlighting positive data tied to a study of the darovasertib and crizotinib combination. UBS initiated coverage with a Buy rating, pointing to darovasertib’s established role in metastatic uveal melanoma and its sales potential. These analyst positions were reported alongside the company updates and the insider purchase.
What this filing shows
The filing documents a meaningful insider purchase by a board director and supplements that disclosure with details about recent clinical enrollment, an executive appointment, and the stance of several analysts. The information presented links the insider transaction to a period of active development in IDEAYA’s oncology pipeline and continued external coverage by sell-side firms.
Note: The article references InvestingPro’s valuation and subscriber tips as reported in the company filing.